Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2024-02-05 00:00:00 ET · period of report 2024-02-01 · accession 0001610717-24-000044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-02-05 | 2024-02-01 | CHRS | Wahlstrom Mats | Dir | M - OptEx | $1.67 | +60.0K | 100.0K | +150% | +$100.2K |
| DM | 2024-02-05 | 2024-02-01 | CHRS | Wahlstrom Mats | Dir | M - OptEx | $0.00 | -60.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-01 | M | A | 14,997 | $1.67 | 54,997 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-01 | M | A | 44,991 | $1.67 | 99,988 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-02-01 | M | D | 44,991 | $0.00 | 0 | D | $1.67 · — to 2024-03-10 | 44,991 Common Stock | (F2) The option is fully vested and exercisable. |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-02-01 | M | D | 14,997 | $0.00 | 0 | D | $1.67 · — to 2024-03-10 | 14,997 Common Stock | (F2) The option is fully vested and exercisable. |